SecBot SecBot

PRFX

PRF Technologies Ltd.
Nasdaq· Pharmaceutical Preparations· Inc. L3· CIK 0001801834 Biotech & Drug Discovery
$0.7230 −0.02 (−2.30%)
Oct 26 4:00 PM ET · prev $0.7400
Market cap
$2.5M
Nano cap
1 year
−89.0%
from $6.60 · Oct 27
30 days
−25.6%
from $0.9720
52-week range
$0.7120–6.60
−89% from high · low Oct 19
Avg volume 20D
32.9K
shares / day
Short interest
27.6K
≈0.8% of shares · −59.7%
Days to cover
1.0
at average volume
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
20
analyzed by SecBot
SecBot read MIXED 8 reports · 90 days
Balance 1 bearish · 2 bullish · 1 mixed · 4 neutral oldest → newest, height = score
Avg score ·High conf. 3/8
Strongest NEUTRAL PRF Technologies issued a shareholder letter highlighting a strengthened balance sheet with $11M cash and…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InstitutionsBULLISH

    Q2 2026: 3 added (0 new), 0 trimmed or exited.

  • Short sellersCOVERING

    Short interest −59.7% to 27.6K shares. 1.0 days to cover, ≈0.8% of shares.

  • TrendDOWNTREND

    21% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
CITADEL ADVISORS LLCDOUBLED28,575$39.4K
UBS Group AGDOUBLED10,415$14.4K
MORGAN STANLEYADD2,783$3.8K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Oct 2024
Recent actions
DateFirmActionRating
Oct 24, 2024Maxim Group
DOWNGRADE
DOWNGRADEHold
Jun 26, 2024Maxim Group
REITERATE
REITERATEBuy

Earnings setup

Estimates
PeriodEPS est.Range30D rev.Revenue
Current Q———$0.00
Next Q———$0.00
Current FY———$0.00
Next FY———$0.00
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Oct 23, 2026
Earnings
PRF Technologies Issues Letter to Shareholders Highlighting $11.0 Million Cash Position, Entering Phase 2 Trial of OcuRing™-K and GridFeed™ Opportunity in AI Data Center Power
Preliminary cash, including short-term deposits, of approximately $11.0 million as of September 30, 2026, and total liabilities of approximately…
Sep 3, 2026
Earnings
PRF Technologies Provides First Half 2026 Business Update Highlighting Significant Progress Across Healthcare and AI Energy Business
FDA cleared the IND for OcuRing™-K, enabling a U.S. multi-center Phase II trial in cataract surgery with patient enrollment expected in the second…
Jul 15, 2026
Press release
PRF Technologies Expands DeepSolar Predict™ Platform with Battery-to-Revenue Intelligence, Extending AI-Driven Revenue Optimization Across Solar and Energy Storage Assets
New Capability Builds on Recently Completed Real-World Validation of DeepSolar Predict™ as the Solution Advances Toward Planned Commercial Launch…
Jun 25, 2026
Press release
PRF Technologies Reports Expanded Preclinical Results for PRF-110 in Head-to-Head Comparison with Approved Benchmark
Additional data reported by an independent research firm show comparable analgesic efficacy to ZYNRELEF alongside slower absorption and enhanced…
May 28, 2026
Press release
PRF Technologies Advances DeepSolar Predict™ Toward Commercial Launch as AI Platform Targets Revenue Optimization Across Renewable Energy Markets
Platform builds on NVIDIA Connect participation and previously announced weather-domain patent filing to address forecasting accuracy, imbalance…

Short side

FINRA· Sep 30, 2026
27,647
shares short
-59.7%
vs prior settlement
1.0
days to cover
≈0.8%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 23, 2026 SEC
PRF Technologies issued a shareholder letter providing preliminary, unaudited financial highlights for the nine months…
6-K — Impact 4/10
Oct 23, 2026 SEC
PRF Technologies issued a shareholder letter highlighting a strengthened balance sheet with $11M cash and $2.5M…
PRESS-RELEASE — Impact 5/10
Oct 23, 2026 Earnings
PRF Technologies Issues Letter to Shareholders Highlighting $11.0 Million Cash Position, Entering Phase 2 Trial of OcuRing™-K and GridFeed™ Opportunity in AI Data Center Power
Preliminary cash, including short-term deposits, of approximately $11.0 million as of September 30,
Sep 28, 2026 SEC
PRF Technologies disclosed receipt of an activist demand from S.H.N. Financial Investments Ltd., which holds ~5.7% of…
6-K — Impact 7/10
Jun 30, 2026 Inst.
CITADEL ADVISORS LLC — DOUBLED
28,575 shares ($39.4K)
Jun 30, 2026 Inst.
UBS Group AG — DOUBLED
10,415 shares ($14.4K)
May 26, 2026 Press
PRF Technologies announced positive preclinical head-to-head results for PRF-110 vs. ZYNRELEF in a pig incisional pain…
Impact 5/10
Apr 28, 2026 Press
PRF Technologies announced FDA clearance of its IND application for OcuRing™-K, a sustained-release intraocular ring…
Impact 4/10

SecBot reports

20 filings · 2 press releases · 2 bullish · 5 bearish · 3 mixed · 10 neutral
All PRFX filing & press-release reports (22)